

Ticket #: \_\_\_\_\_

Telephone:

## **Dexedrine/Dexedrine Spansule®** dextroamphetamine sulfate

Request Time:

PHYS	ICIAN CERTII	FICAT	TON PRI	OR AU	THORIZAT	ION F	ORM		
A request for the patient identifies sulfate). Based on recent clinical benefit plan. Please fill out the fo	al information, we r	equire n	more inform	ation befo	re this prescrip				
A. Member Information Patient Name:			Dlan Name	/Dlan ID:					
Pauent Name.			Plan Name/Plan ID:						
Patient ID:			Patient Da	te of Birth:	Patient Contact Phone #:				
B. Physician Information									
Physician Name:		Physician Address:							
Physician DEA #:	Physician Phone		Physician Fax #:						
Drug Name and Strength:	Direction (SIG):			QTY and Days Supply		NDC #:			
C. Pharmacy Information Pharmacy Name:  D. Clinical Information (Please file	NABP	tion: circle a		Pharmacy Phone #: Phar Phar that apply)			:		
<ol> <li>Does the patient have a current diagnosis of Attention Deficit (ADD) or Attention Deficit with Hyperactivity (ADHD)?</li> </ol>							YES	NO	
2. Does the patient have ADD/ADHD symptoms in more than one setting (ex. school, work, & home)?						YES	NO		
3. Does the patient have a diagnosis of narcolepsy?						YES	NO		
4. Has the patient been evaluated for other causes of excessive daytime sleepiness (ex. insufficient sleep syndrome, upper airway resistance syndrome, depression)?								YES	NO
Dosing Recommendations:									
ADD/ADHD: 2.5 – 40 mg NARCOLEPSY: 5-60 mg po c									
Authorized Medical Signature:					_				

Request Date:

## When Completed Return To:

Date:

ProCare PBM Clinical Division, 1267 Professional Parkway, Gainesville, GA 30507 1-866-965-Drug (3784) / Fax # 866-999-7736

\*\*Please note that this form is to be completed by the prescribing physician. This form and its contents are permissible under HIPAA as the protected health information (PHI) contained in this letter is only being used for purposes related to the provision of treatment, payment and healthcare operations (TPO). HIPAA does restrict the communication of PHI with providers for TPO related purposes.